Printed from Voxsanity (voxsanity.com.au) — NCT07258147 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07258147
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 to 75 years who have a relatively good level of physical functioning (as measured by a standard medical scale called ECOG, scored 0 to 2).
- People who have been diagnosed with stage IV non-small cell lung cancer or extensive-stage small cell lung cancer that has spread to the liver, with at least one liver tumour measuring 1 cm or more.
- People whose cancer has stopped responding to, or who could not tolerate, previous treatment with platinum-based chemotherapy and a type of immunotherapy called a PD-1/PD-L1 inhibitor.
- People whose liver is functioning at an adequate level, as confirmed by specific blood test results within accepted ranges (confirm with trial site).
- People who are expected to live for at least 3 months.
- People whose major organs — including heart, lungs, liver, kidneys, and bone marrow — are working adequately, with no severe dysfunction or immune deficiency conditions.
- People whose recent blood tests (taken within one week before joining) show that blood cell counts and kidney and liver function are within the required ranges (confirm with trial site for specific values).
- People who are willing to join the trial voluntarily and sign a written consent form.
- People who are willing and able to follow the trial schedule and meet its requirements.
- People who are willing to provide blood and tissue samples for research testing.
- People who a radiation specialist has assessed as having no medical reasons preventing them from receiving liver radiotherapy, and who agree to receive immunotherapy, chemotherapy, and radiotherapy as part of the trial.
- People of childbearing potential who agree to use effective contraception during the trial and for at least 6 months after the last treatment, who have a negative pregnancy test within 7 days before joining, and who are not breastfeeding; and male participants whose partners could become pregnant, who agree to use effective contraception during the trial and for 6 months after the last dose.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have an active autoimmune disease, or a history of certain autoimmune conditions such as lung inflammation, eye inflammation, bowel or liver inflammation, hormone gland problems, blood vessel inflammation, heart muscle inflammation, kidney inflammation, or thyroid conditions (note: thyroid conditions that are well controlled with hormone replacement therapy may still be eligible — confirm with trial site); people who have previously had liver radiotherapy or a liver transplant; or people with a history of liver scarring at a significant level, high blood pressure in the liver's blood vessels, or episodes of confusion caused by liver failure.
- People with a congenital or acquired immune system deficiency, including HIV infection, active hepatitis B, active hepatitis C, or a combined hepatitis B and C infection.
- People with serious or uncontrolled heart conditions, including moderate-to-severe heart failure, unstable chest pain (angina), a heart attack within the past year, or significant irregular heart rhythms that require medical treatment.
- People who had a serious infection or significant other illness in the 4 weeks before the first trial treatment.
- People who have previously received a transplanted organ or bone marrow/stem cells from another person.
- People who have had another type of cancer in the past 5 years.
- People who are known to be allergic to any of the medicines used in this trial or their ingredients.
- Women who are pregnant or breastfeeding, or people of childbearing potential who are not willing to use effective contraception during the trial.
- People with a more severe level of liver insufficiency, classified as Child-Pugh class B or C (confirm with trial site).
- People who the trial investigator determines have any other reason that would make participation unsafe or unsuitable.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Principal Investigator: You Lu, Principal Investigator
Phone: +86 15982378768
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Sichuan University
Registry
ClinicalTrials.gov
Start date
31 October 2026
Est. completion
31 December 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
ORR
Can't join this trial?
Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.